CN103874492B - 不对称脲及其医学应用 - Google Patents

不对称脲及其医学应用 Download PDF

Info

Publication number
CN103874492B
CN103874492B CN201280008805.XA CN201280008805A CN103874492B CN 103874492 B CN103874492 B CN 103874492B CN 201280008805 A CN201280008805 A CN 201280008805A CN 103874492 B CN103874492 B CN 103874492B
Authority
CN
China
Prior art keywords
compound
purposes
pharmaceutically acceptable
acceptable salt
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280008805.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN103874492A (zh
Inventor
S.加西亚鲁比奥
C.皮特拉
C.朱利亚诺
Z.李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heersen Health Care Co Ltd
Original Assignee
Helsinn Healthcare SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helsinn Healthcare SA filed Critical Helsinn Healthcare SA
Priority to CN201611088800.9A priority Critical patent/CN106995403B/zh
Publication of CN103874492A publication Critical patent/CN103874492A/zh
Application granted granted Critical
Publication of CN103874492B publication Critical patent/CN103874492B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
CN201280008805.XA 2011-02-25 2012-02-23 不对称脲及其医学应用 Active CN103874492B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611088800.9A CN106995403B (zh) 2011-02-25 2012-02-23 不对称脲及其医学应用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/CN2011/000298 WO2012113103A1 (en) 2011-02-25 2011-02-25 Asymmetric ureas and medical uses thereof
CNPCT/CN2011/00298 2011-02-25
US201161466070P 2011-03-22 2011-03-22
US61/466070 2011-03-22
PCT/US2012/026315 WO2012116176A2 (en) 2011-02-25 2012-02-23 Asymmetric ureas and medical uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201611088800.9A Division CN106995403B (zh) 2011-02-25 2012-02-23 不对称脲及其医学应用

Publications (2)

Publication Number Publication Date
CN103874492A CN103874492A (zh) 2014-06-18
CN103874492B true CN103874492B (zh) 2016-12-07

Family

ID=46719417

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201611088800.9A Active CN106995403B (zh) 2011-02-25 2012-02-23 不对称脲及其医学应用
CN201280008805.XA Active CN103874492B (zh) 2011-02-25 2012-02-23 不对称脲及其医学应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201611088800.9A Active CN106995403B (zh) 2011-02-25 2012-02-23 不对称脲及其医学应用

Country Status (41)

Country Link
US (3) US8658797B2 (enExample)
EP (1) EP2678017B1 (enExample)
JP (1) JP6077468B2 (enExample)
KR (2) KR20140014186A (enExample)
CN (2) CN106995403B (enExample)
AP (1) AP3768A (enExample)
AR (1) AR085398A1 (enExample)
AU (1) AU2012220531B2 (enExample)
BR (1) BR112013021566B1 (enExample)
CA (1) CA2820767C (enExample)
CL (1) CL2013002412A1 (enExample)
CO (1) CO6771450A2 (enExample)
CY (1) CY1118947T1 (enExample)
DK (1) DK2678017T3 (enExample)
DO (1) DOP2013000195A (enExample)
EA (1) EA027374B1 (enExample)
EC (1) ECSP13012893A (enExample)
ES (1) ES2628386T3 (enExample)
GE (1) GEP20156319B (enExample)
HR (1) HRP20170997T1 (enExample)
HU (1) HUE035039T2 (enExample)
IL (1) IL227941A (enExample)
LT (1) LT2678017T (enExample)
MA (1) MA34968B1 (enExample)
ME (1) ME02845B (enExample)
MX (1) MX347587B (enExample)
MY (1) MY164354A (enExample)
NI (1) NI201300070A (enExample)
PE (1) PE20141000A1 (enExample)
PH (1) PH12013501757A1 (enExample)
PL (1) PL2678017T3 (enExample)
PT (1) PT2678017T (enExample)
RS (1) RS56033B1 (enExample)
SG (1) SG192138A1 (enExample)
SI (1) SI2678017T1 (enExample)
SM (1) SMT201700407T1 (enExample)
TN (1) TN2013000346A1 (enExample)
TW (1) TWI579273B (enExample)
UA (1) UA113510C2 (enExample)
WO (2) WO2012113103A1 (enExample)
ZA (1) ZA201307071B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106995403A (zh) * 2011-02-25 2017-08-01 赫尔辛卫生保健公司 不对称脲及其医学应用

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105073133B (zh) 2012-12-21 2021-04-20 Aveo制药公司 抗gdf15抗体
TWI690512B (zh) * 2014-03-07 2020-04-11 瑞士商赫爾辛保健股份有限公司 對位取代的不對稱脲及其醫療用途
RU2686317C2 (ru) * 2015-04-24 2019-04-25 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Замещенные 1,2,5-триметил- и 2,2,6,6-тетраметил-4-аминопиперидины, обладающие антиишемическим действием
UA122267C2 (uk) 2016-03-22 2020-10-12 Хелсінн Хелскеа Са Асиметричні бензолсульфонілсечовини і їх застосування в медицині
JPWO2019031471A1 (ja) * 2017-08-07 2020-11-26 国立大学法人広島大学 脂肪性肝疾患の治療剤及び肥満症の治療剤
EP3672960A2 (en) 2017-08-21 2020-07-01 Acadia Pharmaceuticals Inc. Compounds, salts thereof and their use for the treatment of diseases
FI3672954T3 (fi) 2017-08-21 2025-10-16 Acadia Pharm Inc Yhdisteitä, niiden suoloja ja niiden käyttö sairauksien hoidossa
EP3724176B1 (en) 2017-12-11 2022-01-26 Helsinn Healthcare SA Fumarate salt of (r)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl) urea, methods of preparation, and uses thereof
EP3542799A1 (en) * 2018-03-22 2019-09-25 Helsinn Healthcare SA New centrally-active ghrelin agonist and medical uses thereof
TN2023000216A1 (en) 2021-03-10 2025-04-03 Jnana Therapeutics Inc Small molecule inhibitors of mammalian slc6a19 function
MA64831B1 (fr) 2021-06-02 2025-05-30 Helsinn Healthcare Sa Dérivés d'urée pipéridine pour une utilisation en tant qu'agents inotropiques
EP4404926A4 (en) * 2021-09-22 2025-08-13 Univ Duke COMPOSITIONS FOR THE TREATMENT OF FOOD ADDICTION AND CHEMICAL DEPENDENCE AND METHODS OF MAKING AND USING THE SAME
WO2024158862A1 (en) * 2023-01-25 2024-08-02 University Of North Texas Health Science Center Thiourea antioxcompounds with neuroprotective activity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1993325A (zh) * 2004-08-02 2007-07-04 阿斯利康(瑞典)有限公司 作为组胺h3受体配体的哌啶衍生物

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5285174A (en) * 1976-01-05 1977-07-15 Yoshitomi Pharmaceut Ind Ltd Novel urea or thiourea derivatives
AU7545894A (en) 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
WO1998006709A1 (en) 1996-08-14 1998-02-19 Takeda Chemical Industries, Ltd. Cyclic urea compounds, their production and use as herbicides
US6399619B1 (en) 1999-04-06 2002-06-04 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
IL151164A0 (en) * 2000-03-06 2003-04-10 Acadia Pharm Inc Azacyclic compounds for use in the treatment of serotonin related diseases
GB0011838D0 (en) 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
US20030022891A1 (en) * 2000-12-01 2003-01-30 Anandan Palani MCH antagonists and their use in the treatment of obesity
JP2004520423A (ja) 2001-03-01 2004-07-08 アストラゼネカ・アクチエボラーグ Ｃｃｒ５モジュレーターとしてのｎ−ピペリジニル化合物
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
US6673829B2 (en) * 2001-09-14 2004-01-06 Novo Nordisk A/S Aminoazetidine,-pyrrolidine and -piperidine derivatives
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
SE0200919D0 (sv) 2002-03-25 2002-03-25 Astrazeneca Ab Chemical compounds
CA2498272A1 (en) * 2002-09-11 2004-03-25 Merck & Co., Inc. Piperazine urea derivatives as melanocortin-4 receptor agonists
AU2003284402A1 (en) 2002-11-15 2004-06-15 Yamanouchi Pharmaceutical Co., Ltd. Antagonist to melanin-concentrating hormone receptor
EP1640361B9 (en) * 2003-06-30 2015-11-04 Sumitomo Chemical Company, Limited Asymmetric urea compounds and process for producing asymmetric compounds by asymmetric conjugate addition reaction using the same as catalyst
US7115767B2 (en) * 2003-07-18 2006-10-03 Abbott Laboratories Tetraline derivatives as ghrelin receptor modulators
EP1725538B1 (en) * 2004-02-10 2007-08-29 Janssen Pharmaceutica N.V. Pyridazinone ureas as antagonists of a4 integrins
US20050261278A1 (en) * 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
GB0412865D0 (en) 2004-06-09 2004-07-14 Glaxo Group Ltd Chemical compounds
SE0401657D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
CA2577060A1 (en) * 2004-08-13 2006-02-23 Amgen Inc. Substituted benzofused heterocycles
JP2008518014A (ja) * 2004-10-27 2008-05-29 ニューロゲン コーポレイション Ｃｂ１拮抗薬としてのジアリール尿素
US20080306055A1 (en) 2004-12-21 2008-12-11 Astrazeneca Ab Heterocyclic Mchr1 Antagonists And Their Use In Therapy
US7829589B2 (en) 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
US20080300251A1 (en) * 2005-09-05 2008-12-04 Sattigeri Jitendra A Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors
AU2006310518A1 (en) * 2005-11-01 2007-05-10 High Point Pharmaceuticals, Llc Pharmaceutical use of substituted amides
AR058277A1 (es) * 2005-12-09 2008-01-30 Solvay Pharm Gmbh N- sulfamoil - piperidin - amidas, composiciones farmaceuticas que las comprenden y procedimiento para su preparacion
CA2657660A1 (en) 2006-07-12 2008-01-17 Merck & Co., Inc. Substituted pyrazoles as ghrelin receptor antagonists
JP2008042298A (ja) 2006-08-02 2008-02-21 Olympus Corp 固体撮像装置
GB0701992D0 (en) 2007-02-02 2007-03-14 7Tm Pharma As Grehlin Receptor Modulators
WO2008141057A1 (en) * 2007-05-08 2008-11-20 Auspex Pharmaceuticals, Inc. Deuterated pimavanserin 1- (4-flu0r0benzyl) -3- (4-isobutoxybenzyl) -1- ( l-methyl-piperidin-4-yl) -urea
GB0710865D0 (en) 2007-06-06 2007-07-18 Glaxo Group Ltd Novel compounds
GB0710863D0 (en) * 2007-06-06 2007-07-18 Glaxo Group Ltd Novel compounds
EP2187746A4 (en) 2007-08-06 2011-01-19 Univ California PREPARATION OF NEW 1,3-SUBSTITUTED UREASES AS A HOLDER OF SOLUBLE EPOXY HYDROLASE
CA2700331A1 (en) * 2007-09-21 2009-03-26 Acadia Pharmaceuticals, Inc. Co-administration of pimavanserin with other agents
UA100527C2 (en) 2007-10-10 2013-01-10 Астразенека Аб Benzothiazoles as ghrelin receptor modulators
WO2009092293A1 (en) 2008-01-18 2009-07-30 Shanghai Targetdrug Co., Ltd. Pyrollidine-based compounds
WO2009089659A1 (en) 2008-01-18 2009-07-23 Shanghai Targetdrug Co., Ltd. Pyrollidine-based compounds
USRE49686E1 (en) * 2008-09-19 2023-10-10 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use of same
WO2010111353A1 (en) * 2009-03-25 2010-09-30 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
WO2011060397A1 (en) * 2009-11-16 2011-05-19 Schering Corporation Substituted amino heterocycles useful as hiv antagonists
WO2012113103A1 (en) * 2011-02-25 2012-08-30 Helsinn Healthcare S.A. Asymmetric ureas and medical uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1993325A (zh) * 2004-08-02 2007-07-04 阿斯利康(瑞典)有限公司 作为组胺h3受体配体的哌啶衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Modulators of the human CCR5 receptor. Part 1: Discovery and initial SAR of 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas;Jeremy N.Burrows,et al.;《Bioorganic & Medicinal Chemistry Letters》;20041206;第15卷;第25-28页 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106995403A (zh) * 2011-02-25 2017-08-01 赫尔辛卫生保健公司 不对称脲及其医学应用
CN106995403B (zh) * 2011-02-25 2020-04-24 赫尔森保健股份公司 不对称脲及其医学应用

Also Published As

Publication number Publication date
AP3768A (en) 2016-08-31
CY1118947T1 (el) 2018-01-10
CA2820767A1 (en) 2012-08-30
EP2678017A4 (en) 2015-05-20
DK2678017T3 (en) 2017-07-24
WO2012113103A1 (en) 2012-08-30
CO6771450A2 (es) 2013-10-15
BR112013021566A2 (pt) 2016-11-08
KR20140014186A (ko) 2014-02-05
CN106995403B (zh) 2020-04-24
CN103874492A (zh) 2014-06-18
AU2012220531B2 (en) 2017-02-23
JP6077468B2 (ja) 2017-02-08
ME02845B (me) 2018-01-20
US10407390B2 (en) 2019-09-10
US8658797B2 (en) 2014-02-25
AU2012220531A1 (en) 2013-09-26
TW201245151A (en) 2012-11-16
ZA201307071B (en) 2014-06-25
CA2820767C (en) 2019-06-25
PL2678017T3 (pl) 2017-09-29
KR101907573B1 (ko) 2018-10-15
TN2013000346A1 (en) 2015-01-20
MY164354A (en) 2017-12-15
MX2013006974A (es) 2013-10-07
US9751836B2 (en) 2017-09-05
SG192138A1 (en) 2013-08-30
SI2678017T1 (sl) 2017-07-31
NZ615283A (en) 2015-09-25
CL2013002412A1 (es) 2014-02-07
AP2013007123A0 (en) 2013-09-30
BR112013021566B1 (pt) 2020-11-17
SMT201700407T1 (it) 2017-09-07
ECSP13012893A (es) 2013-11-29
KR20180075703A (ko) 2018-07-04
IL227941A0 (en) 2013-09-30
UA113510C2 (uk) 2017-02-10
EA201300946A1 (ru) 2014-06-30
RS56033B1 (sr) 2017-09-29
PE20141000A1 (es) 2014-08-09
EP2678017A2 (en) 2014-01-01
HUE035039T2 (en) 2018-05-02
MA34968B1 (fr) 2014-03-01
JP2014518543A (ja) 2014-07-31
WO2012116176A3 (en) 2014-04-24
IL227941A (en) 2017-10-31
US20180044293A1 (en) 2018-02-15
US20140121210A1 (en) 2014-05-01
WO2012116176A2 (en) 2012-08-30
MX347587B (es) 2017-05-03
US20120220629A1 (en) 2012-08-30
DOP2013000195A (es) 2014-12-15
LT2678017T (lt) 2017-06-26
GEP20156319B (en) 2015-07-10
ES2628386T3 (es) 2017-08-02
TWI579273B (zh) 2017-04-21
CN106995403A (zh) 2017-08-01
NI201300070A (es) 2014-03-11
AR085398A1 (es) 2013-09-25
PT2678017T (pt) 2017-06-26
PH12013501757A1 (en) 2013-10-14
HRP20170997T1 (hr) 2017-10-06
EA027374B1 (ru) 2017-07-31
EP2678017B1 (en) 2017-04-05

Similar Documents

Publication Publication Date Title
CN103874492B (zh) 不对称脲及其医学应用
CA2932010C (en) Urea derivative or pharmacologically acceptable salt thereof
JP2013545740A (ja) バニロイド受容体リガンドとしての置換された複素芳香族カルボキサミド誘導体および尿素誘導体
US10577384B2 (en) Substituted asymmetric ureas as modulators of ghrelin receptor activity
JP2013534229A (ja) バニロイド受容体リガンドとしての置換された環状カルボキサミド誘導体および尿素誘導体
JP2010540422A (ja) チエノピリミジン化合物類
HK1189360B (en) Asymmetric ureas and medical uses thereof
HK1189360A (en) Asymmetric ureas and medical uses thereof
TW202502346A (zh) 作為at2r拮抗劑的雜環化合物及其用途
NZ615283B2 (en) Asymmetric ureas and medical uses thereof
OA16546A (en) Asymmetric ureas and medical uses thereof.
JP2008534641A (ja) 二環式化合物の調製方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: Lugano, Switzerland

Patentee after: Heersen health care Co Ltd

Address before: Lugano, Switzerland

Patentee before: HELSINN HEALTHCARE SA